What You Should Know:
- Proscia, a leader in artificial intelligence (AI)-powered pathology solutions, and Nucleai, a leading spatial AI biomarker company, announced a strategic partnership today. This collaboration aims to revolutionize precision medicine by integrating Nucleai's advanced biomarker technology with Proscia's Concentriq® software platform.
- By harnessing the power of AI and digital pathology, this partnership offers the potential to fundamentally improve the
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation
What You Should Know:
- Foresite Capital, a San Francisco, CA-based healthcare and life sciences investment firm, announced today the successful closing of its sixth fund with a significant $900M in capital commitments. This new fund fuels Foresite's mission to invest in groundbreaking technologies across the healthcare spectrum.
- Fund VI attracted a diverse group of limited partners, including university endowments, charitable foundations, medical institutions, pension funds,
Read More
Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery
What You Should Know:
- Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies.
- These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas.
Unveiling the Power of Clinico-Genomic Data
The datasets offer a unique combination of longitudinal
Read More
Tempus AI Files for IPO, Eyes Over $600M in Funding for AI-Powered Precision Medicine
What You Should Know:
- Tempus AI, a leader in artificial intelligence (AI)-powered precision medicine, filed with the Securities and Exchange Commission (SEC) on Monday to raise up to $100M in an initial public offering (IPO). Industry analysts, however, believe this figure might be a placeholder, with the actual target amount closer to $600M.
- Founded in 2015 and headquartered in Chicago, Illinois, Tempus AI reported $562M in revenue for the fiscal year ending March 31,
Read More
Phenomix Sciences Raises $7.8M to Acclerate Obesity Precision Medicine Adoption
What You Should Know:
- Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047.
- The company has also been awarded a $2.3 million Phase II Small Business Innovation Research (SBIR) Grant
Read More
Zephyr AI Secures $111M to Democratize Precision Medicine with Explainable AI
What You Should Know:
- Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group.
- The company plans to use this round of funding to refine its technology to fortify its extensive collection of training and validation datasets, crucial for robust AI models, deliver results even faster, and expand its scientific and commercial
Read More
Sano Genetics Secures $11.4M to Turbocharge Precision Medicine Research
What You Should Know:
- Sano Genetics, a software company that is revolutionizing precision medicine research, has secured $11.4M in new funding.
- This latest investment, led by Plural with participation from existing investors MMC Ventures, Episode 1, and Seedcamp, brings the company's total funding to $22M.
Revolutionizing Precision Medicine Research
Founded by a trio of visionary minds - Patrick Short (CEO), Charlotte Guzzo (COO), and William Jones (CTO) - Sano Genetics is
Read More
Drug-Gene Interactions: Minimizing Risk with Pharmacogenomics
Every individual responds differently to medications, and their reactions can vary greatly. While a specific drug may be effective for one person with no adverse effects, another individual may experience a negative reaction to the same medication. Pharmacogenomic (PGx) testing enables the identification of patients who are prone to adverse drug reactions, individuals who are more likely to benefit from specific medications and those who may require adjusted dosages. As adverse drug reactions
Read More
Prenosis Awarded $4.8M in NIH Grants to Enable Precision Medicine for Sepsis
What You Should Know:
Prenosis, Inc., a Chicago, IL-based AI company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH). The grants will study the use of Prenosis's Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial
Read More
Expectations For The Connected Care Business In The Years Ahead
Though we seldom see their use in our modern world and, even then, only in fiction, there was a time when it was common for people to actually use things like crystal balls and divining rods to try to uncover unknown yet valuable information. As unbelievable as it may seem, soothsayers peered into crystal balls aiming to help seekers look into the future for guidance, while prospectors would rely earnestly on divining rods as they attempted to locate underground riches of water or oil.
While
Read More
